CONy 2020 | Treating relapsing-remitting MS aggressively at disease presentation

Abhijit Chaudhuri, DM, MD, PhD, FACP, FRCP, FEAN, Queen’s Hospital, Romford, UK, discusses the benefits of aggressively treating relapsing-remitting multiple sclerosis (MS) at presentation. With traditional therapeutic strategies, patients do not receive high efficacy treatments until 2 to 3 years after disease presentation. By this point, there is little prospect for function recovery. Therefore, high efficacy treatment options should not be delayed and be an available option at presentation. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.